Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- EX1.AU
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Exopharm Ltd
- Exchange
- (AU ,
- Currency
- AUD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 27.34M
- Ent value
- 25.10M
- Price/Sales
- 31.59
- Price/Book
- 10.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 28.09%
- 1 year return
- -8.00%
- 3 year return
- -75.29%
- 5 year return
- -54.56%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
EX1.AU does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 31.59 |
| Price to Book | 10.07 |
| EV to Sales | 29.01 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.19B |
| EPS (TTM) | -0.04 |
| FCF per share (TTM) | -0.01 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 865.40K |
| Gross profit (TTM) | -942.70K |
| Operating income (TTM) | -7.22M |
| Net income (TTM) | -6.48M |
| EPS (TTM) | -0.04 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -108.93% |
| Operating margin (TTM) | -833.89% |
| Profit margin (TTM) | -748.58% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.61M |
| Net receivables | 22.14K |
| Total current assets | 2.67M |
| Goodwill | 0.00 |
| Intangible assets | 200.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 3.08M |
| Accounts payable | 38.41K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 341.40K |
| Total liabilities | 367.88K |
| Shareholder's equity | 2.71M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -2.10M |
| Capital expenditures (TTM) | 197.39K |
| Free cash flow (TTM) | -2.30M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -238.62% |
| Return on Assets | -210.15% |
| Return on Invested Capital | -238.62% |
| Cash Return on Invested Capital | -84.65% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| EX1.AU | S&P500 | |
| Current price drop from All-time high | -99.03% | -0.75% |
| Highest price drop | -99.15% | -56.47% |
| Date of highest drop | 6 Sep 2023 | 9 Mar 2009 |
| Avg drop from high | -62.29% | -11.07% |
| Avg time to new high | 113 days | 12 days |
| Max time to new high | 827 days | 1805 days |
COMPANY DETAILS
Marketcap
27.34M
Marketcap category
Small-cap
Description
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
Australia
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found